A plasma activated ophthalmic solution generating device operable to generate a therapeutic ophthalmic solution for curing epidemic keratoconjunctivitis includes a plasma generating electrode operable to generate a plasma activated ophthalmic solution for epidemic keratoconjunctivitis, wherein the plasma generating electrode is arranged surrounding an insert space where a unit dose ophthalmic eyedrop container with a container body, which seals a certain solution in a sterile state, is inserted; a power supply unit; and a high voltage generating unit, which is connected to the power supply unit, operable to be supplied with power source from the power supply unit and to apply high voltage electric current to the plasma generating electrode. This configuration makes it possible to provide a novel and effective therapeutic ophthalmic solution for epidemic keratoconjunctivitis (EKC).

A plasma activated ophthalmic solution generating device operable to generate a therapeutic ophthalmic solution for curing epidemic keratoconjunctivitis includes a plasma generating electrode operable to generate a plasma activated ophthalmic solution for epidemic keratoconjunctivitis, wherein the plasma generating electrode is arranged surrounding an insert space where a unit dose ophthalmic eyedrop container with a container body, which seals a certain solution in a sterile state, is inserted; a power supply unit; and a high voltage generating unit, which is connected to the power supply unit, operable to be supplied with power source from the power supply unit and to apply high voltage electric current to the plasma generating electrode. This configuration makes it possible to provide a novel and effective therapeutic ophthalmic solution for epidemic keratoconjunctivitis (EKC).

The present invention provides a non-invasive near-infrared light-controlled nanomaterial for the treatment of diabetes and use of an upconversion fluorescent nanomaterial in the preparation of a tool for the treatment of diabetes, wherein the upconversion fluorescent nanomaterial includes an inorganic nanomaterial doped with rare earth elements, and a layer of water-soluble polymer and molecules targeting liver cells, which is on the surface of the nanomaterial. In the treatment of diabetes, there is no need to surgically implant invasive optical fibers in animals, and the upconversion nanomaterial in an organism is excited by near-infrared light with high tissue penetrability. The upconversion material converts the light of near-infrared band into visible light, to activate light-sensitive proteins. This enables the remote control of intracellular glucose metabolism-related signaling pathways independent of insulin with high temporal-spatial resolution, to promote the glycogen synthesis, inhibit the gluconeogenesis, and lower the blood glucose level.

A pharmaceutical composition for an ophthalmic use either in humans or mammalians for a treatment of eye disorders is provided. The pharmaceutical composition includes an effective amount of an oxidizing agent and an effective amount of a photo-sensitizing agent, in combination with pharmaceutically acceptable excipients; the photo-sensitizing agent is a molecule having an absorbance peak in a wavelength range between 340 nm and 440 nm and emits fluorescence in a wavelength range between 450 nm and 600 nm; the oxidizing agent is chosen among molecules, wherein the molecules partially or totally inhibit a mitochondrial electron transport chain activity, wherein the pharmaceutical composition is a liquid formulation further includes one or more substances chosen among: diluents, permeabilizers, disinfectants, buffer systems, salts, antiseptics, and the pharmaceutically acceptable excipients.

A method of distributing microparticles is provided, the method comprising: providing a plurality of microparticles at an insertion site in a medium; applying ultrasound to the insertion site that generates gas bubbles by cavitation at cavitation nuclei located at the insertion site and drives movement of the gas bubbles such that the gas bubbles drive movement of the microparticles into a desired spatial distribution in the tumour. The method may be a method of treating a tumour, and the microparticles may comprise a radioisotope for treating the tumour. Microparticles for use in the treatment of a tumour by the method are also disclosed.

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.

Methods and topical compositions for the treatment of a dermatological disorder are provided. The topical composition includes 5-aminolevulinic acid, at least one penetration enhancer and at least one chelating agent. Further, methods and topical compositions for use in photodynamic therapy are disclosed, in which the topical composition is applied to the affected area of a patient for a period in the range of about 15 minutes to about 10 hours.

Systems, devices, and methods for converting a raw neutron beam to a specified deliverable format having a targeted energy range, size, and direction are described. Embodiments of a neutron beam converter can include numerous regions based on location, function, dimension, and/or constituent material. The regions can include a central region, an intermediate region, a peripheral region, and a frontal region. Materials are also described.

A photodynamic therapy treatment support device is provided with a light source and a distribution information output unit. The light source irradiates a photosensitive substance administered to a body of a subject with light of a specific wavelength bandwidth having energy capable of generating fluorescence from the photosensitive substance without advancing necroses of tumor cells. The distribution information output unit outputs information on a distribution state of the fluorescence generated from the photosensitive substance, based on the fluorescence generated from the photosensitive substance.

Provided herein are magnetically-responsive, photosensitizer based antimicrobial microemulsions and photodynamic nanoplatforms in which a photosensitizer functionally associated with a plurality of superparamagnetic iron oxide nanoparticles are encapsulated. Also provided are methods and processes utilizing the antimicrobial microemulsions and photodynamic nanoplatforms to treat an oral disease, to reduce a microbial population in a pathogenic oral biofilm and to improve the efficacy of a photosensitizer during an antimicrobial photodynamic therapy treatment of an oral disease.